Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers developed a novel TA-encapsulated microneedle applicator that successfully promoted hair growth and reduced inflammation in a C3H/HeJ mouse model of alopecia areata, potentially offering an improved alternative to existing treatments.

Farudodstat may help treat alopecia areata by protecting hair follicles.

This review describes the clinical presentation, diagnosis, and management of adrenomyeloneuropathy, including rehabilitative therapies and spasticity management, and reports no new clinical results.

This discussion highlights that alopecia areata incognita is challenging to diagnose and treat, with systemic corticosteroids potentially leading to remission when local treatments fail.

This study found that flutamide emulgels with 1% Transcutol P enhanced percutaneous absorption through rat skin more effectively than other formulations tested.

This review discusses the evidence supporting Janus kinase inhibitors for alopecia areata and highlights ongoing optimism as phase 3 trials begin, with no new clinical results reported.

This study found that using particle-based antigen delivery in combination with cyanoacrylate skin surface stripping is an effective needle-free method for targeting HIV-1 p24 protein to skin cells, enhancing transcutaneous vaccination potential.

This study reports that a novel UV-based crosslinking process for collagen sponges significantly decreases crosslinking time compared to traditional methods, and supports effective cell proliferation and wound regeneration in a mouse model, without causing abnormal angiogenic or immune responses.

In a mouse model of infected burns, this study found that treatment with recombinant fusion peptide EK significantly decreased Pseudomonas aeruginosa colony count and improved wound healing rates compared to controls.

This case study presents a reversal of hair loss in discoid lupus erythematosus using newer treatments like injectable platelet-rich fibrin.

This study describes three cases where patients with recalcitrant alopecia areata achieved complete hair regrowth on the scalp after treatment with upadacitinib, suggesting it may be beneficial for similar cases, especially those with comorbid atopic dermatitis.

In this study using zebrafish, four bisbenzylisoquinoline derivatives were found to protect hair cells from aminoglycoside-induced damage without reducing antibiotic efficacy, potentially leading to therapies for patients undergoing such treatments.

This review explores the infundibulum's role and importance in skin diseases and emphasizes the need for further research into its biology and potential therapeutic targeting, but it presents no new findings.

This case study observed that a patient with multiple refractory inflammatory conditions, including psoriasis, alopecia areata, and psoriatic arthritis, experienced significant improvements after three months of treatment with upadacitinib. The report suggests potential benefits of upadacitinib for similar conditions, recommending further clinical trials.

This case report describes an 18-year-old male with IFAP syndrome, confirmed by total hair loss, severe photophobia, and characteristic skin changes, marking a rare presentation of the condition.

This study found that the proprietary aptamer TAGX-0003 significantly inhibited IFNγ-induced effects in pre-clinical human models of alopecia areata, promoting hair regrowth and potentially preventing disease relapse.

This study found a severe MBTPS2 gene mutation in a Japanese IFAP syndrome patient, suggesting other factors may influence the syndrome's clinical features compared to previously studied patients.

In this study on mice, a baricitinib-loaded microneedle patch enhanced hair growth in alopecia areata lesions (68% vs control: 33%, p < 0.05), suggesting it may deliver treatment effectively and pain-free, with fewer systemic side effects.

This review assessed randomised clinical trials on the efficacy and safety of topical and systemic JAK inhibitors for alopecia areata, finding significant hair coverage improvement with ritlecitinibe and baricitinibe, though prolonged treatment is often needed to maintain results.

This article discusses alopecia areata, highlighting its autoimmune nature and the lack of FDA-approved treatments, without providing new research findings.

This study developed electrospun nanofibers containing mupirocin for wound treatment, reporting enhanced antibacterial activity, high water absorption, and accelerated wound healing in a rat model, suggesting potential use for severe skin injuries at risk of infection.

This review assessed the clinical and cost-effectiveness of baricitinib, an oral treatment for severe alopecia areata in adults, to inform Canadian reimbursement recommendations, excluding Quebec.

Nanocrystals improve alopecia areata treatment by better targeting hair follicles.

In this study, PRP and Yifu combined with ultrapulsed CO2 lattice laser were found to improve sunken acne scars more effectively than laser alone, enhancing patients' quality of life and reducing adverse events, with a higher effective rate compared to the laser-only group.

This study found that anifrolumab effectively reduced disease activity and allowed for corticosteroid tapering in patients with systemic lupus erythematosus at Kanazawa University Hospital.